BVS
BEARISH
$8.84
Live
Bioventus Inc. · NASDAQ
Target $14.8
(+67.4%)
$5.81
52W Range
$9.53
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 08, 2026
Market cap
$595.53M
P/E
26.79
ROE
13.2%
Profit margin
4.0%
Debt/Equity
1.36
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
BVS shows bearish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Concerns include weak profitability or high valuation.
Key Strengths
Company has established market presence
Key Risks
Premium vs Graham Number ($4.51)
Low profit margin of 4.0%
AI Fair Value Estimate
Based on comprehensive analysis
$2.31
-73.9% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
38
Weak
50
50
40
50
0
AI Verdict
BVS shows bearish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Concerns include weak profitability or high valuation.
Key drivers: Company has established market presence, Premium vs Graham Number ($4.51), Low profit margin of 4.0%
Confidence
35%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
- Trades above Graham Number.
Future
50/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Past
40/100
Historical performance + price trend: Shares moved -36.8% over 5Y and +6.9% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- Thin profit margins.
Health
50/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$8.84
Analyst Target
$14.8
Upside/Downside
+67.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BVS and closest competitors.
Updated 2026-04-07
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BVS
Bioventus Inc.
Primary
|
-36.8% | +662.1% | +6.9% | +32.9% | +2.7% | -3.2% |
|
AVNS
Avanos Medical, Inc.
Peer
|
-72.6% | -56.0% | -17.1% | +9.0% | +14.8% | +6.1% |
|
AVR
Anteris Technologies Global Corp.
Peer
|
-8.8% | -8.8% | +40.4% | +17.2% | -21.5% | -6.6% |
|
ANGO
AngioDynamics, Inc.
Peer
|
-49.3% | +20.9% | +23.6% | +7.9% | +5.1% | +6.4% |
|
BWAY
BrainsWay Ltd.
Peer
|
+163.4% | +1289.2% | +184.8% | +61.0% | -3.2% | -7.8% |
BVS
Bioventus Inc.
Primary
5Y
-36.8%
3Y
+662.1%
1Y
+6.9%
6M
+32.9%
1M
+2.7%
1W
-3.2%
AVN
Avanos Medical, Inc.
Peer
5Y
-72.6%
3Y
-56.0%
1Y
-17.1%
6M
+9.0%
1M
+14.8%
1W
+6.1%
AVR
Anteris Technologies Global Corp.
Peer
5Y
-8.8%
3Y
-8.8%
1Y
+40.4%
6M
+17.2%
1M
-21.5%
1W
-6.6%
ANG
AngioDynamics, Inc.
Peer
5Y
-49.3%
3Y
+20.9%
1Y
+23.6%
6M
+7.9%
1M
+5.1%
1W
+6.4%
BWA
BrainsWay Ltd.
Peer
5Y
+163.4%
3Y
+1289.2%
1Y
+184.8%
6M
+61.0%
1M
-3.2%
1W
-7.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
26.79
Forward P/E
10.1
PEG Ratio
1.19
P/B Ratio
3.22
P/S Ratio
1.05
EV/Revenue
1.61
EV/EBITDA
11.75
Market Cap
$595.53M
Profitability
Profit margins and return metrics
Profit Margin
4.0%
Operating Margin
13.76%
Gross Margin
68.33%
ROE
13.17%
ROA
4.99%
Growth
Revenue and earnings growth rates
Revenue Growth
+2.8%
Earnings Growth
N/A
Q/Q Revenue Growth
+2.77%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.36
Moderate
Current Ratio
1.7
Good
Quick Ratio
1.12
Good
Cash/Share
$0.76
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
68.9%
Op. Margin
13.8%
Net Margin
9.3%
Total Assets
$0.7B
Liabilities
$0.5B
Equity
$0.2B
Debt/Equity
2.47x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
98%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-03-05
$0.24
+10.8% surprise
2025-11-04
$0.15
+30.4% surprise
2025-08-06
$0.21
+6.8% surprise
Healthcare Sector Comparison
Comparing BVS against 166 companies in the Healthcare sector
(15 bullish, 53 neutral, 98 bearish)
P/E Ratio
26.79
This Stock
vs
43.21
Sector Avg
-38.0%
(Discount)
Return on Equity (ROE)
13.17%
This Stock
vs
-44.87%
Sector Avg
-129.4%
(Below Avg)
Profit Margin
4.0%
This Stock
vs
-20.08%
Sector Avg
-119.9%
(Weaker)
Debt to Equity
1.36
This Stock
vs
5.59
Sector Avg
-75.6%
(Less Debt)
Revenue Growth
2.8%
This Stock
vs
119.32%
Sector Avg
-97.7%
(Slower)
Current Ratio
1.7
This Stock
vs
3.38
Sector Avg
-49.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BVS
Bioventus Inc.
|
BEARISH | $595.53M | 26.79 | 13.2% | 4.0% | $8.84 | |
|
AVNS
Avanos Medical, Inc.
|
BEARISH | $607.62M | - | -46.7% | -67.0% | $13.09 | Compare |
|
AVR
Anteris Technologies Global Corp.
|
BEARISH | $496.86M | - | -301.9% | -% | $5.11 | Compare |
|
ANGO
AngioDynamics, Inc.
|
BEARISH | $492.14M | - | -15.3% | -9.0% | $11.94 | Compare |
|
BWAY
BrainsWay Ltd.
|
NEUTRAL | $490.8M | 68.11 | 11.3% | 14.6% | $12.26 | Compare |
BVS
Bioventus Inc.
BEARISH
Mkt Cap
$596M
P/E
26.8
ROE
13.2%
Price
$8.84
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-20 | SINGLETON MARK LEONARD | Chief Financial Officer | Stock Award | 18,625 | - |
| 2026-03-13 | CHURCH KATRINA J | Officer | Stock Award | 6,955 | - |
| 2026-03-13 | D'ADAMIO ANTHONY | General Counsel | Stock Award | 17,636 | - |
| 2026-03-13 | SINGLETON MARK LEONARD | Chief Financial Officer | Stock Award | 13,500 | - |
| 2026-03-13 | CLAYPOOLE ROBERT E. | Chief Executive Officer | Stock Award | 33,500 | - |
| 2026-03-11 | MCMURRY-HEATH MICHELLE | Director | Sale | 12,000 | $105,439 |
| 2026-02-13 | CHURCH KATRINA J | Officer | Stock Award | 4,375 | - |
| 2026-02-13 | D'ADAMIO ANTHONY | General Counsel | Stock Award | 12,980 | - |
| 2026-02-13 | SINGLETON MARK LEONARD | Chief Financial Officer | Stock Award | 20,153 | - |
| 2026-01-09 | CLAYPOOLE ROBERT E. | Chief Executive Officer | Stock Award | 93,750 | - |
| 2025-12-04 | NOHRA GUY P | Director | Sale | 10,000 | $75,658 |
| 2025-11-07 | MCMURRY-HEATH MICHELLE | Director | Sale | 17,701 | $131,255 |
SINGLETON MARK LEONARD
Chief Financial Officer
2026-03-20
18,625 shares
CHURCH KATRINA J
Officer
2026-03-13
6,955 shares
D'ADAMIO ANTHONY
General Counsel
2026-03-13
17,636 shares
SINGLETON MARK LEONARD
Chief Financial Officer
2026-03-13
13,500 shares
CLAYPOOLE ROBERT E.
Chief Executive Officer
2026-03-13
33,500 shares
MCMURRY-HEATH MICHELLE
Director
2026-03-11
12,000 shares
·
$105,439
CHURCH KATRINA J
Officer
2026-02-13
4,375 shares
D'ADAMIO ANTHONY
General Counsel
2026-02-13
12,980 shares
SINGLETON MARK LEONARD
Chief Financial Officer
2026-02-13
20,153 shares
CLAYPOOLE ROBERT E.
Chief Executive Officer
2026-01-09
93,750 shares
NOHRA GUY P
Director
2025-12-04
10,000 shares
·
$75,658
MCMURRY-HEATH MICHELLE
Director
2025-11-07
17,701 shares
·
$131,255
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
5 analysts
Barrington Research
2026-03-06
Outperform
Outperform
Craig-Hallum
2026-03-06
Buy
Buy
Barrington Research
2026-02-09
Outperform
Past News Coverage
Recent headlines mentioning BVS from our newsroom.
Newest → oldest
No matching news yet.